All right. We will get underway here. A lot to cover. Thank you very much for joining us on our next session. I am Michael Yee, Global Head of Biotech Research at UBS, and I am thrilled to have the CEO of Oruka Therapeutics, Lawrence Klein, with us. Lawrence, I was just talking with you. Congratulations on all the achievements in 2026. Had a lot of positive phase II readouts, and has propelled your stock to basically near 52-week highs, and one of the few mid-cap biotechs that is near their all-time highs, while the rest of the XBI sort of pulled back, and I think it is a testament to some of your data.
If I may just offer you the opportunity to talk a little bit about your two lead drugs, give us a backdrop of what you have shown, specifically with ORKA-001, a long-acting and I would say superior efficacy profile than AbbVie's SKYRIZI, and a second drug, which is a long-acting IL-17, which could be very competitive to BIMZELX for all those UCB folks out there. Talk about those two programs.
Yeah, great. Happy to. Thanks, Mike. Thanks for having us, and thanks everybody for joining. I think that was a great intro, set the stage. It is definitely been an action-packed 2026 for us.
Yeah.
I think the headline has been the phase II data that has emerged from our 001 program. The thesis behind Oruka was that there is one more meaningful step we can take in the product profile of biologics in psoriatic disease, primarily plaque psoriasis and psoriatic arthritis is our main focus, where IL-23p19 and IL-17A/F have really emerged as the best targets to treat that condition, and they are highly effective and very, very well tolerated. They have allowed us to reach some pretty remarkable kind of efficacy outcomes. Now the next frontier is sort of perfect the product profile, and there has been huge investments made in oral formats of these molecules that target these pathways. Those have consistently sort of fallen short of the efficacy of the best biologics, and really the appeal is a daily pill, sometimes with the food effect.
What we have is, we think, something more compelling than that, which is some of the highest levels of efficacy we've ever seen in this indication space, with the potential to dose as infrequently as once to twice per year. When we go out and do our market research, we think is a winning profile, in a market that's maybe $40 billion and growing. Just tremendous potential for these products to reward all stakeholders. With our phase II data, we've shown PASI 100, which is fully clear skin, going from a baseline of PASI score of maybe 20, which is 20%-25% of body surface area. Think of like entire torso covered in a psoriasis plaque, pretty severe disease, to complete clearance, which means a dermatologist does a full skin survey and can't find psoriasis on the body.
We have rates in the 60% at week 16, and that's actually grown to over 70 at the six-month mark with no additional dosing beyond induction. Those are basically the highest rates of efficacy that have ever been observed with any mechanism, and in the format with ORKA-001 of an IL-23, which is essentially one of the cleanest mechanisms of all of I&I. We have safety data now on over 250 subjects, which is pretty similar to placebo. To achieve those rates of efficacy, very high tolerability in a format that we'll see in December, we think could potentially be dosed once a year.
By the way, just for the context of that, as people learn this, I know there's a lot of specialists and people who have seen some of this data, but AbbVie's SKYRIZI, I cover AbbVie, which is going to do like $20 billion in SKYRIZI, their PASI 100s are between 35%-50%.
Yeah, that's right.
Let's call it 45%, and you're showing 50% better, which is 60%-70%.
That's right.
AbbVie's SKYRIZI is not showing that.
Yeah, about a 20 percentage point delta.
Yeah. Okay. Those PASI 100 scores have been reported out. They are a very strong step up from a very good drug, SKYRIZI. What is most important is that while you have shown good induction data and the potential for once every six-month or 12-month dosing, maintenance of those responses is also important. You have some data coming up on that. I just want to ask you what you think about that to complete the profile for this drug.
Yeah. That has always been the core of the differentiation we were shooting for with ORKA-001. Glad to see the efficacy delta. Obviously, that is very powerful. This is an extended half-life molecule with an approximately 100-day half-life. To our knowledge, that is the longest half-life of any monoclonal in all of biopharma, so it is really a special molecule that we think could get to very, very long dose intervals. We have dosed subjects in induction. We have shown data out to six months with no additional dosing that shows a continued deepening in the response. This next test in December will be 52-week data, and it will include a group of subjects that have not received a dose since their induction regimen, so basically a year out from last dose. If we can maintain a good level of response in that group, I think we can confidently say we have a once-a-year treatment.
We do want to have a six-month option on the label regardless of what the 52-week data shows. We think that is important in a preference-driven market to have flexibility around dosing. When we take that profile out and test it with physicians and patients, the response is really remarkable. We think it could really be a category-winning profile.
AbbVie's SKYRIZI has 35%-50%, let us call it 45%-50%, I will even give them the benefit of the doubt, very strong results, and it is a $20 billion drug, and that is dosed once every three months in psoriasis. When you look at those PASI 100 rates and dose once every three months, the maintenance of that at the one-year time point, meaning I guess their last dose was three months ago, they have approximately 80% of those patients at the beginning that did maintain that PASI 100.
That's right.
Your design of your study is unique because you give the induction, then you're following these patients. Those who got a dose at six months, we followed them to the end of the year, and some people did not have any more dosing other than the induction dose. Those patients that had the induction dose got to that 70%, and they're going to follow them to the full year. What would be a good maintenance of response in a six-month regimen and a 12-month regimen?
Right.
Once every 12 months, yeah.
Right. We have a group of subjects who started out clear at six months.
Yep.
They are randomized onto an arm where they do not get any additional active drug again since induction, so a year out from last response. The question we will be asking is, what is their maintenance of response? What percentage of them maintain PASI 100? If they did not maintain PASI 100, how significant is the disease that has recurred? You can sometimes have subjects who see a very small amount of recurrence.
The disease is not actually returning to baseline, it is just fluctuating.
That is right.
Sometimes you will see someone come in with a zero fully clear skin, next visit there will be a 0.4.
Literally one spot or plaque popped up, and that's no longer a PASI 100.
It's a very, very stringent bar. Patient may not even know that's there, probably wouldn't want to seek redosing. Next visit may be totally clear again. There is some fluctuation around that.
Yeah, for AbbVie, it's about a 20% fluctuation, right? Because 80% maintenance of that.
That's right. If you did this exact same experiment with a SKYRIZI or a TREMFYA, actually it looks pretty similar with anything. ICOTYDE has similar results. If you continued to dose, you would end up with about 75%-80%, 85%. That's sort of a perfect score on this test. You really can't expect to do better than that because that's what you maintain with a That's sort of just natural fluctuation of the disease. If we got something like that, I think you can confidently say this is a once-a-year drug for really anybody. It's as good maintenance as a frequently dosed regimen with once-a-year dosing. That would be truly spectacular.
By the way, starting from higher PASI 100 rates too.
Exactly.
You are getting more people to clear and they are all maintaining that. Okay, but go ahead.
Exactly. Yeah, and then we think there is a window just below that.
Call it 50%-70% maintenance, where we would have a once-a-year regimen for most people. Once a year is going to work great for most people, and then we would have a six-month option that maybe some people needed if they saw significant disease coming back. Again, that person who came back to a, say, a 0.4 at week 52, probably perfectly happy on a once-a-year regimen. We see it as kind of two categories where 50%-70%, we would say once a year with a six-month option, 70% plus into the 80s, we would say unequivocally once a year for everybody. Still want a six-month on the label, if in case anyone needs it, but we-
Can I frame that a little bit? You are looking at people who only got induction. They got their 60%-70% PASI 100, and then we are following them for the whole year, but they only got an induction regimen.
They literally only got one dosing for the whole year. We call that once every 12 months. You are telling me that a high end, factually, like AbbVie, could be 80% of the maintenance, 50%-70% is also obviously pretty good.
What about the once every six-month arm? Those at the six-month time point got another injection. They were at their PASI 100, and obviously they could maintain 80% or 50%-70%, but isn't that long maintenance pretty good for once every six months too? Or you keep talking about annual.
I was going to come back to that because we think with the PK we have, we likely will have annual dosing for at least a good percentage of patients. I think really the question is it Because we maintain trough antibody levels above what's done with more frequently dosed therapies. We think we are going to have some once-a-year dosing. The question is just, how much do you need that six-month option? But stepping back, when we started the program, all the market research said even six months, big winner. Even with equal efficacy, even with that 35%-45% PASI 100, with the 60% plus PASI 100. I mean, I think at this point we are sort of, is this going to be a $5 billion drug or a $7 billion or a $10 billion plus? This is really sort of-
Okay
distinguishing great and even greater.
Okay
with the profile.
When does this data come?
This is December.
This is maintenance, December.
Yeah, and that's sort of a function of the trial finished enrollment last December.
We have 52-week visits in December, and our team's going to work wonders to turn the data.
We'll look at the two arms. One is those who got it for once every six months, and those who got it only one administration for the whole year. Those people had PASI 100s. If we can get 50%-70% or 80% maintenance, each one of those scenarios is very strong. Like you said, if you're getting 80% and once every six or once every 12, that is a home run.
Yep, exactly.
All right. When this data comes in December, obviously you are already planning for phase III. What is the plan for phase III? How are you thinking about this design?
Yeah, we have basically seen what we need to see to design the phase IIIs, because again, we want to have six month and one year on the label. There is not really anything more we need to see to go forward with that. We have been moving forward with getting ready to start phase III. A key step for that is an end-of-phase discussion based on the EVERLAST-B data that we showed earlier this year. Everything is on track for a fast phase III start. Our guidance is first half of next year. This December data will sort of complete the picture of efficacy, dose interval.
We have got 250 subjects, tolerability data, over 100 patient years experience. You will have a pretty de-risked late-stage program in not too much time here.
One arm would be once every six months. Safe to say one arm is probably annual. I think I can make that
Yep
guess. It is against placebo. Would you have an active comparator, or what would you do?
Yeah, we would have an active comparator. Most psoriasis studies have.
Yeah.
We get the question, would you run it against SKYRIZI? We do not need to do that, we think, and there is obviously some risk involved in doing something like that. It may be a different active comparator. STELARA has been used in a lot of studies with IL-23p19.
That could be a natural choice. We haven't shared details of the phase III designs. We'll do that after engagement with the agency.
Okay. It's not like in January. It would take some time, like at the updates at the conference.
Guidance is first half of next year.
Got it. When I think about IL-23, I think about the fact that SKYRIZI and TREMFYA, both of those two, as you said, and some others, are a $50 billion class of drug. Both are very good, but you have a very convenient, very long-acting program. You take a look at what the market has recently observed, which is that this class of drug is going to be great, but even in a class like DUPIXENT, which everyone is familiar with, Apogee, a company that you guys are from, because those drugs all came out of Paragon Labs, okay? AbbVie bought Apogee for a once every three-month dosing form of DUPIXENT, and that company got taken out for $10 billion. $10 billion. How do you think about that framework of what AbbVie just did for Apogee for $10 billion?
I think your market cap is around $7 and change, and you have a second drug, which we will get to in a moment. To what extent do pharma BD folks think about this? We have only seen one. Now, we have seen one, it was a pretty important one. AbbVie did buy a YTE company. I think Wall Street is trying to struggle with, was that just a one-off with AbbVie? Are you just going to go out and develop a whole phase III program? How do you think about that, the business development strategy?
Yeah. Do not have a crystal ball. Hard to predict. I think over the past few years, you have certainly seen, I think, increasing recognition of the fundamentals of these kinds of profiles.
Yeah
Ultra-long-acting profiles in I&I. Even when there is not an efficacy delta, I think we have something unique with ORKA-001 in that we have potentially both. There has never been a once-year anything in any chronic immune disease.
Right
With an efficacy delta. I think the fundamentals are extremely strong in terms of the demand, in terms of the momentum behind these markets. I think that is something that maybe people underestimated a few years ago. You see it now, the psoriasis space continues to grow. BIMZELX launched a couple years ago, has created like $50 billion of market cap for UCB. ICOTYDE is launching, going very, very well for J&J, but not really taking share from biologics, probably growing the market.
Right.
I think there is a scenario where that $50 billion becomes $75 billion in a few years, and if you take a meaningful share of that, I think for anybody with a patent cliff that you are trying to make up for, there are not that many
Right
drugs with the potential that we see.
Point number one is that in many different indications, and certainly within derm, a more convenient drug ultimately, and assuming even similar efficacy, gets more market share. That has been seen because as you know, IL-23s and psoriasis are out to once every three months now. The older drugs are once a month, et cetera. Once every three month, SKYRIZI, TREMFYA, going to do north of $20 billion-$30 billion. Yours is once every six months and possibly once every 12 months.
The efficacy is another step higher.
I think if you followed along with those precedents, then that would make a whole lot of sense. It is just a matter of how the profile looks and what pharma company's interest is in that type of program.
Yeah, absolutely. Our focus is, we think there is tremendous potential with these, and we are positioned to take them all the way if that is sort of what the crystal ball holds for us. We are well capitalized. We have the capabilities to do that. We think it is underestimated the extent to which a biotech company can succeed commercially in these markets.
Galderma and others.
Arcutis.
Yeah.
I mean, BIMZELX, when UCB launched BIMZELX, I think they were a $10 billion market cap company.
without a big franchise to sort of rebate off of, and they've gotten great access for BIMZELX, and it's done incredibly well.
Okay. I think that is a good picture for IL-23 ORKA-001. We'll see this maintenance data. I got to be honest, I don't think that changes the overall context of things. I think the data's going to be pretty strong and good by you executing along this and let business development activity engage where it may be. If I may ask, because you do have data on the second program. It's a little bit confusing for me because your second program is a long-acting IL-17A/F and is an improved formulation, an improved antibody over other products like BIMZELX. Can you talk about your 16-week psoriasis data coming up in the first quarter and how to think about that? Because here, I'm not sure that the efficacy bar would necessarily be raised, whereas with IL-23, it was a nice step up.
Efficacy is great, but here the efficacy may not necessarily be totally differentiated, but you do have more convenient dosing. How should we think about this wheel?
Yeah. We think we're in a fairly unique position where we have two very high probability of success, potentially multi-billion dollar assets in the pipeline. Not that easy to find companies at our stage that could say that. ORKA-002 is a novel molecule, similar mechanism of action to BIMZELX with an ultra-long-acting profile. IL-17A/F has sort of emerged as this new approach to targeting the IL-17 family of cytokines that drives higher efficacy in psoriasis, psoriatic arthritis, and HS.
We're in two parallel phase II studies with ORKA-002, psoriasis, plaque psoriasis, and then HS as well. The data, first quarter next year will be the plaque psoriasis data. Sometimes we get the question, why would you want to have both IL-23 and IL-17 in psoriasis? That we think is very clear that they're complementary. They serve fairly non-overlapping segments of the patient population. 17s really play their best role in people with concurrent psoriatic arthritis, and that's 25%-30% of the population. The history of the indication, you see SKYRIZI and TREMFYA coexisting with COSENTYX and TALTZ, and all four of those being
mega blockbusters.
mega blockbusters.
Okay.
IL-17A/F is a newer target. BIMZELX is the only approved product. The only other clinical asset that we're aware of is MoonLake's sonelokimab, which has obviously had some challenges with the data. So we think even equal efficacy with BIMZELX, equal efficacy to BIMZELX in the first quarter with that long-acting potential, twice annual in psoriasis, quarterly in HS is what we're shooting for. Could have tremendous potential in these markets.
Okay. What is the data we're getting in Q1? 16-week PASI data?
That's right.
What is a good result? Basically, what does BIMZELX show at 16 weeks?
Yeah. BIMZELX-like is what we're shooting for on safety and tolerability. BIMZELX has shown high 50s to low 60s typically of PASI 100, and in the 80s for PASI90. Pretty similar to what we showed with 001.
Okay.
We have a dose range finding study that we will be reading out in the first quarter, so three different dose levels that are fairly comparable to what BIMZELX tested in their phase II. We think it is a smaller study, so there could be just variability due to sampling variation, but an overall picture that looks similar to BIMZELX is what we are shooting for and we would consider a fantastic.
Which I think if I heard you said 50%-60% is the PASI 100.
Yep
number. And you have shown 61% and 63% with your IL-23, which is great and better than SKYRIZI. Here, 50%-60% is quite good. The reason why it is not used so much in psoriasis is because of the AE profile for BIMZELX, which includes oral candidiasis. So that is the one thing as to why you would use SKYRIZI, which is pretty good AE profile. So on your product, would you expect, given the longer exposure, what would you think about? Is your oral candidiasis numbers going to be the same? Could it be higher? Could it be lower? Does it matter?
We do not think it matters that much, honestly. You look at BIMZELX has a higher rate than COSENTYX and TALTZ, and it is obviously done incredibly well. Oral candidiasis is really viewed as a nuisance AE at most. It is very easily treated, tends not to recur. A vast majority of people, if they get it, only get it once. Very easy to manage. We think the kind of assumption going in should be that we would have similar rates in the long run.
What, should I look at the label? What rate do you guys
It's in the around 10%
Okay
but varies from into the mid-teens down to high single digits. With a small study, you could have higher or lower rates. If we have lower rates, we'd be the first to say, "Look, in a longer run study, you might see more similar." I think we'd want to say the same if it ended up a little higher. I think the baseline assumption should be rates, tolerability profile will be similar given the mechanism of action
Yeah
is the same.
Yeah.
And exposures we are testing are fairly similar.
Meaning the Cavg is basically the same?
Mm-hmm. Right. Yeah.
Therefore, I agree, cross-trial comparison, if it is higher, and we are not saying clinically meaningfully higher than 10%.
Yep
then that is not a difference. If it was lower, I also probably would not say that your drug has lower oral candidiasis because biologically the exposure of the drug is the same.
Yeah.
Yeah. Now, one of the advantages of why BIMZELX is a mega blockbuster drug is because it has great application in psoriatic arthritis where the IL-23s are not so good. There, BIMZELX has found a great opportunity. That is why it is big, it is because of psoriatic arthritis. That has nothing to do with scleritis. What information at all would we get here to say that it will work the same? Maybe we do not need to see that. We will just assume it is the same as BIMZELX, but could there be any insights there?
You really got to run a separate study for that because it is a very different assessment that is pretty specialized to rheumatology.
Yeah.
That is really what drives. You really need to run a separate dermatology and rheumatology study. But I think it is a very safe assumption if you see good efficacy in plaque psoriasis with a mechanism like this, that it is going to have an effect in PsA as well.
What would be the next milestone after this Q1 data? You expect to run a big phase IIb?
This is a dose range-finding study, so this would be the study that ungates to phase III.
Yeah.
We may want to see a little more data than the week 16 to just validate that we've got six-month dosing potential before we embarked on a phase III. We do want to get that going fairly quickly.
Yep.
Yeah, so 16-week data first quarter, 28-week data for that will help to validate that six-month profile, and also studying that in HS, which is off to a good start as well. Could be a big year next year for the ORKA-002 program.
Now, one of the things that happened, I think it was in the summer, is that we can appreciate you've got potentially two blockbuster drugs in two mega classes, yet a sister company, Spyre, also covered by UBS, also has an IL-23, all came out of Paragon Labs, but they've been developing it for the IBD indications. Then both of you guys both put out eight-Ks, noting that the license agreements from Paragon Labs allows now the derm company to go into IBD and the IBD company to look at derm. How should I interpret that, and was that a reflection of big pharma companies and others saying, "Well, wait a second. I don't know, Lawrence.
Like, if I do this and then someone goes out and buys Spyre and then they go run into derm, wait a second, they're going into my space." What came out of that to amend this to allow both of you guys now to both do these indications?
Yeah. The driver was to each have the potential in the long run
to use our IL-23 antibody in any therapeutic area. So originally, there was a restriction where we couldn't take ours into IBD, Spyre couldn't take theirs outside of IBD. We mutually agreed to take away that restriction. It has a time delay on it, so neither company can start immediately in those therapeutic areas. Really, the thinking was, Oruka is going to live and die on our monotherapies in psoriatic disease.
I think if a strategic's going to be interested in Oruka, they're going to be interested in the potential in these monotherapies.
That's right.
I think Spyre is going to live and die on their combinations in IBD.
Yep.
If a strategic's going to be interested in Spyre, it's going to be for that. If we're both independent companies down the road and we're $30 billion market cap, we'll probably be competing in some-
That's right.
some areas.
That's right.
I personally would see that as a fantastic outcome, and I think others would as well. We see it as a way to open up that opportunity longer term, because that's the right thing to do for each of our companies.
I'm going to make a prediction and say in a few years, neither of you are going to be independent, but what do I know?
Better you than me.
All right. Well, thank you very much, Lawrence. I appreciate it, and we look forward to the data coming up.
Thanks, Mike. Really enjoyed it.